Journal of Palliative Care & Medicine
ISSN: 2165-7386
Elli, J Palliat Care Med 2024, 14:5
Editorial Open Access

# Harnessing Mitotic Catastrophe for Targeted Cancer Treatment

**Giuliani Elli***

*Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy*

**Abstract**

Mitotic catastrophe is a mechanism of cell death that occurs during mitosis when cells experience severe mitotic stress, often due to DNA damage, defective spindle assembly, or improper chromosome segregation. In the context of cancer, the high rate of mitotic errors makes cancer cells particularly susceptible to mitotic catastrophe. This article explores the role of mitotic catastrophe in cancer therapy and the strategies to harness it for targeted cancer treatment. Microtubule-targeting agents, DNA-damaging agents, checkpoint inhibitors, and Aurora kinase inhibitors are some of the therapeutic agents that can induce mitotic catastrophe in cancer cells. By selectively targeting cancer cells, these agents offer the potential to improve therapeutic outcomes while minimizing harm to normal tissues. However, challenges such as selective targeting, resistance mechanisms, and the identification of biomarkers for response need to be addressed for the successful implementation of these treatments. This approach represents a promising frontier in cancer therapy, with the potential to revolutionize treatment protocols and enhance patient outcomes.

## Introduction

Cancer remains one of the most formidable challenges in modern medicine, demanding innovative strategies to effectively target and eliminate malignant cells. One promising avenue of research is the exploitation of mitotic catastrophe a mechanism of cell death that occurs during mitosis when cells encounter severe mitotic stress. Understanding and harnessing mitotic catastrophe could provide new pathways for targeted cancer treatments, potentially improving therapeutic outcomes and reducing side effects. This article delves into the mechanisms behind mitotic catastrophe, its role in cancer therapy, and how it can be leveraged for more effective cancer treatments [1].

## Understanding mitotic catastrophe

Mitotic catastrophe is a form of cell death that occurs due to errors during mitosis, the process of cell division. These errors can arise from various sources, including DNA damage, defective spindle assembly, and improper chromosome segregation. When cells cannot properly repair these mitotic errors, they undergo mitotic catastrophe, leading to cell death either during mitosis or in the subsequent interphase [2].

## The key mechanisms involved in mitotic catastrophe include:

**DNA Damage Response (DDR):** Cells with extensive DNA damage activate DDR pathways. If the damage is irreparable, it triggers mitotic catastrophe to prevent the propagation of defective cells.

**Spindle Assembly Checkpoint (SAC):** This checkpoint ensures that all chromosomes are correctly attached to the mitotic spindle before anaphase begins. Defects in SAC can lead to chromosome missegregation and mitotic catastrophe [3].

**Apoptotic Pathways:** Cells undergoing mitotic catastrophe often activate apoptotic pathways, leading to programmed cell death. This serves as a fail-safe mechanism to eliminate potentially harmful cells.

Mitotic Catastrophe in Cancer Therapy

Cancer cells often exhibit high rates of mitotic errors due to their rapid and uncontrolled division. This makes them particularly susceptible to mitotic catastrophe. By inducing or enhancing mitotic stress, it is possible to selectively target cancer cells while sparing normal, healthy cells [4].

**Strategies to Induce Mitotic Catastrophe in Cancer Cells**

Microtubule-Targeting Agents: Drugs like taxanes (e.g., paclitaxel) and vinca alkaloids (e.g., vincristine) disrupt microtubule dynamics, leading to defective spindle formation and mitotic arrest. Prolonged mitotic arrest often results in mitotic catastrophe and cell death.

DNA-Damaging Agents: Chemotherapeutic agents such as doxorubicin and cisplatin cause extensive DNA damage. This damage overwhelms the cell's repair mechanisms, triggering mitotic catastrophe [5].

Checkpoint Inhibitors: Inhibiting proteins involved in SAC, such as BubR1 or Mad2, can force cells into mitosis with unattached or misattached chromosomes, leading to catastrophic mitotic failure.

Aurora Kinase Inhibitors: Aurora kinases play crucial roles in chromosome alignment, segregation, and cytokinesis. Inhibitors of Aurora kinases can disrupt these processes, inducing mitotic catastrophe.

## Challenges and future directions

While targeting mitotic catastrophe presents a promising approach to cancer treatment, several challenges must be addressed:

Selective Targeting: Ensuring that treatments selectively induce mitotic catastrophe in cancer cells while minimizing damage to normal cells is crucial. Strategies to achieve this include exploiting cancer-specific vulnerabilities and combining therapies for synergistic effects [6].

Resistance Mechanisms: Cancer cells can develop resistance to drugs that induce mitotic catastrophe. Understanding these resistance

***Corresponding author:** Giuliani Elli, Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy, E-mail: giulianielli@gmail.com

**Received:** 02-May-2024, Manuscript No. jpcm-24-139313; **Editor assigned:** 04-May-2024, PreQC No. jpcm-24-139313 (PQ); **Reviewed:** 18-May-2024, QC No. jpcm-24-139313; **Revised:** 22-May-2024, Manuscript No. jpcm-24-139313 (R); **Published:** 29-May-2024, DOI: 10.4172/2165-7386.1000644

**Citation:** Elli G (2024) Harnessing Mitotic Catastrophe for Targeted Cancer Treatment. J Palliat Care Med 14: 644.

mechanisms and developing strategies to overcome them is essential for long-term therapeutic success.

Biomarkers for Response: Identifying biomarkers that predict a patient's response to mitotic catastrophe-inducing therapies can help tailor treatments to individual patients, maximizing efficacy and minimizing side effects.

## Discussion

Harnessing mitotic catastrophe for targeted cancer treatment offers promising opportunities for more effective and selective cancer therapies. By inducing mitotic failure in cancer cells, it is possible to exploit their susceptibility to mitotic stress and selectively promote their death, sparing healthy cells. This discussion will explore the advantages, challenges, and future directions of employing mitotic catastrophe-based strategies in cancer treatment [7].

### Advantages of mitotic catastrophe-based cancer treatment

Selective Targeting of Cancer Cells: Cancer cells often experience a higher degree of mitotic stress compared to normal cells due to their rapid division and genomic instability. By targeting the pathways and mechanisms involved in mitotic catastrophe, it is possible to selectively induce cell death in cancer cells without significantly impacting normal cells. This specificity enhances the therapeutic index of treatment regimens.

Enhanced Efficacy of Chemotherapeutic Agents: Combining mitotic catastrophe-inducing agents with traditional chemotherapeutic drugs, such as microtubule-targeting agents or DNA-damaging agents, can increase the overall efficacy of cancer treatment. These agents can work synergistically to amplify mitotic stress and induce cell death.

Overcoming Drug Resistance: Cancer cells often develop resistance to chemotherapy over time, limiting treatment effectiveness. The selective induction of mitotic catastrophe may provide a new mechanism to target resistant cancer cells, as these cells are more prone to mitotic stress and failure [8].

Reduced Toxicity: By selectively targeting cancer cells, mitotic catastrophe-based treatments may reduce the toxicity associated with traditional chemotherapy, as healthy cells are less likely to undergo mitotic catastrophe.

### Challenges and considerations

Selective Targeting: Achieving selective targeting of cancer cells while avoiding normal cell damage remains a significant challenge. Advanced targeting strategies, such as the use of cancer-specific biomarkers or drug delivery systems, may offer solutions to this issue.

Resistance Mechanisms: Cancer cells often develop resistance to mitotic catastrophe-inducing agents, necessitating a deeper understanding of the molecular pathways involved in resistance. Identifying and targeting these pathways could enhance the long-term effectiveness of these therapies.

Combination Therapies: Combining mitotic catastrophe-inducing agents with other treatment modalities, such as immunotherapy or radiation, could offer a synergistic effect. However, the optimal combination and sequence of these treatments require further research and clinical evaluation.

Biomarker Identification: The identification of biomarkers that predict patient response to mitotic catastrophe-based therapies will allow for more personalized treatment approaches. These biomarkers can help guide the selection of patients most likely to benefit from these therapies [9].

### Future directions

Innovative Drug Development: Continued research into the development of new mitotic catastrophe-inducing agents, as well as refining existing drugs, will be crucial for advancing this approach. The focus should be on enhancing drug specificity and minimizing potential side effects.

Clinical Trials and Validation: Comprehensive clinical trials are essential to validate the efficacy and safety of mitotic catastrophe-based therapies. These trials should focus on different cancer types and patient populations to establish a broad applicability.

Mechanistic Studies: A deeper understanding of the molecular and cellular mechanisms underlying mitotic catastrophe will provide insights into the most effective ways to target cancer cells selectively.

Personalized Medicine: Integrating personalized medicine approaches into mitotic catastrophe-based treatments will enhance the overall efficacy of cancer therapy. Understanding the unique genetic and molecular profiles of individual patients can facilitate tailored treatment strategies [10].

## Conclusion

Harnessing mitotic catastrophe for targeted cancer treatment presents a promising avenue for improving the outcomes of cancer therapy. By selectively inducing mitotic failure in cancer cells, these treatments can offer a more effective and less toxic alternative to traditional chemotherapy. Addressing the challenges associated with selective targeting, drug resistance, and biomarker identification will be essential for advancing this approach and realizing its full potential. Continued research and clinical trials will play a crucial role in determining the optimal implementation and integration of mitotic catastrophe-based therapies into cancer treatment protocols. By inducing catastrophic mitotic failure specifically in cancer cells, it is possible to achieve effective tumor control while reducing harm to normal tissues. Continued research into the mechanisms of mitotic catastrophe, along with the development of innovative therapeutic agents and combination strategies, will be key to realizing the full potential of this approach. As our understanding of mitotic catastrophe deepens, it holds the promise of transforming cancer treatment and improving outcomes for patients worldwide.

### References

1. Engel L George (1977) The Need for a New Medical Model: A Challenge for Biomedicine. Science 196: 129-136.
2. Stajduhar KI, Davies B (2005) Variations in and factors influencing family members' decisions for palliative home care. Palliat Med 19: 21-32.
3. Wilson DM, Cohen J, Deliens L, Hewitt JA, Houttekier D (2013) The preferred place of last days: results of a representative population-based public survey. J Palliat Med 16: 502-508.
4. Abel J, Kellehear A, Karapliagou A (2018) Palliative care-The new essentials. Ann Palliat Med 7: 3-14.
5. Nishimura F, Carrara AF, Freitas CE (2019) Effect of the Melhorem Casa program on hospital costs. Rev Saude Publica 53: 104.
6. Greer S, Joseph M (2015) Palliative care: A holistic discipline. Integr Cancer Ther 15: 1-5.
7. Sokol D (2014) Don't forget the relatives. BMJ 349.
8. Noble B (2016) Doctors talking to friends and families. BMJ Support Palliat Care 6: 410-411.

9. Küchler T, Bestmann B, Rapport S, Henne-Bruns D, Wood-Dauphinee S (2007) Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10 year survival results of a randomised trial. J Clin Oncol 25: 702-708.

10. Borrell-Carrió F, Suchman AL, Epstein RM (2004) The biopsychosocial model 25 years later: principles, practice, and scientific inquiry. Ann Fam Med 2: 576-582.